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ABSTRACT
Introduction: The treatment of type 2 diabetes
mellitus (T2DM) continues to pose challenges
for clinicians and patients. The dramatic rise in
T2DM prevalence, which has paralleled the rise
in obesity, has strained the healthcare system
and prompted the search for therapies that not
only effectively treat hyperglycemia, but are
also weight neutral or promote weight loss. In
most clinical situations after diagnosis, patients
are advised to adopt lifestyle changes and
metformin is initiated to help control blood
glucose levels. However, metformin may not be
tolerated, or may not be sufficient for those
with higher glucose levels at diagnosis. Even
among those who have initial success with
metformin, the majority eventually require
one or more additional agents to achieve their
treatment goals. Because T2DM is a progressive
disease, the requirement for combination
treatment escalates over time, driving the need
for therapies with complementary mechanisms
of action.
Methods and Results: Online public resources
were searched using ‘‘empagliflozin’’, identifying
32 articles in PubMed, and 12 abstracts
presented at the 2013 American Diabetes
Association meeting. Peer-reviewed articles
and abstracts describing preclinical studies and
clinical trials were retrieved, and relevant
publications included in this review. Trials
registered on clinicaltrials.gov were searched
for ongoing empagliflozin studies.
Conclusion: The sodium–glucose co-transporter
2 (SGLT2) inhibitors are of great interest since
they provide a novel, insulin-independent
mechanism of action. The SGLT2 inhibitor
empagliflozin has demonstrated promising
pharmacodynamic and pharmacokinetic properties.
In clinical trials, empagliflozin has demonstrated
a good efficacy and safety profile in a broad
range of patients with T2DM, and appears to be
an attractive adjunct therapeutic option for the
treatment of T2DM. Ongoing trials, including
patients with T2DM and comorbidities such as
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hypertension, are expected to provide
important additional data, which will further
define the role of empagliflozin in a growing
movement toward individualized approaches to
diabetes care.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
disease characterized by elevated blood glucose
levels, insulin resistance, and relative
insufficiency of insulin production. The
prevalence of T2DM is rising dramatically
around the world. For example, in the United
States (US) the number of adults with diabetes
increased by 75% during the time between a
survey conducted during 1988–1994 to a second
survey in 2005–2010 [1]. In the US, as
elsewhere, this increase is generally seen in
parallel with the rise in the prevalence of
obesity, which is now at epidemic proportions
[1, 2]. The total economic burden associated
with diabetes treatment and lost productivity is
substantial; in the US alone, these costs have
been calculated at 245 billion USD for 2012 [3].
After diagnosis, treatment for T2DM is
initially focused on lifestyle management and
includes changes in dietary choices,
consumption patterns, and the institution of
exercise regimens to reduce weight, enhance
insulin sensitivity, and lower blood glucose
levels [4]. If these strategies do not achieve the
desired goals for blood glucose [or if at diagnosis
a patient’s glycosylated hemoglobin (HbA1c)
level is [7.5%], then guidelines recommend
pharmacotherapy at diagnosis [4]. Metformin is
recommended as initial therapy with addition
of sulfonylureas, thiazolidinediones, dipeptidyl
peptidase (DPP)-4 inhibitors, glucagon-like
peptide-1 (GLP-1) receptor agonists, sodium–
glucose co-transporter 2 (SGLT2) inhibitors, or
insulin as needed [4]. These agents have
different mechanisms of action, and different
effects on insulin resistance, insulin secretion, and
weight. Therefore, the risk/benefit ratio of each
drug, or drug combination, needs consideration in
light of therapeutic goals and potential safety
concerns for individual patients [4].
Of these different classes of anti-diabetes
drugs, the SGLT2 inhibitors are the newest.
These agents help regulate blood glucose levels
by blocking the reuptake of filtered glucose in
the proximal tubule, leading to significant
excretion of glucose via the urine, which is a
novel and insulin-independent approach
(Fig. 1) [5]. Clinical experience with SGLT2
inhibitors has increased since the approvals of
dapagliflozin [in November 2012 by the
European Medicines Agency (EMA) and in
January 2014 by the US Food and Drug
Administration (FDA)] and canagliflozin (in
March 2013 by the FDA and November 2013
by the EMA). A third agent, empagliflozin, is in
late-stage clinical trials in a global development
program, including the US and Europe. In this
review, the available data from these trials,
along with preclinical studies, are surveyed to
determine the potential value of empagliflozin
in the treatment of patients with T2DM.
REVIEW METHODS
During November 2013, PubMed (US National
Library of Medicine, Bethesda, MD, USA) and
the Scientific Sessions Online Resources
(American Diabetes Association, Alexandria,
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VA, USA) were searched using the term
‘‘empagliflozin’’, identifying 32 articles in
PubMed, and 12 clinical abstracts presented at
the 2013 American Diabetes Association
meeting. Peer-reviewed articles and abstracts
describing preclinical studies and clinical trials
were retrieved, and relevant publications
included in this review. The reference lists of
relevant publications were reviewed for
potential additional reports. Trials registered
on clinicaltrials.gov were searched for ongoing
empagliflozin studies, using the search term
‘‘empagliflozin’’ and the criteria ‘‘Phase 3’’. The
analysis in this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by the author.
Discovery and Brief History of SGLT
Inhibitors
For over a century, a naturally occurring
botanical glucoside has been known to
contribute to glucosuria in animals and
humans [6]. This active compound was
eventually identified as phlorizin and it was
established that increased glucose excretion
could help regulate blood glucose levels [6].
Early studies showed that phlorizin inhibited
the transport of glucose in a variety of tissues,
including the kidney and small intestine [7, 8].
Further investigation identified phlorizin as a
competitive inhibitor of the SGLT1 and SGLT2
proteins, which are membrane-embedded
proteins responsible for reabsorption of
glucose from the glomerular filtrate in the
kidney. SGLT1 is also found in the small
intestine, where it is responsible for absorption
of glucose and galactose.
In a diabetic rat model, phlorizin treatment
increased glucose concentration in urine, and
normalized plasma glucose levels in the absence
of hypoglycemia, in both fasting and fed states
[9]. Phlorizin also improved insulin sensitivity
[9]. While these properties made phlorizin very
interesting, it was ultimately unsuitable for
Fig. 1 Key agents and sites of action for type 2 diabetes mellitus drugs. DPP dipeptidyl peptidase, GI gastrointestinal, GIP
gastric inhibitory polypeptide, GLP glucagon-like peptide, SGLT2 sodium–glucose co-transporter 2
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clinical development for several reasons. Firstly,
phlorizin is broken down in the gastrointestinal
tract, and must thus be administered
intravenously; secondly, the active metabolite,
phloretin, is a potent inhibitor of facilitative
glucose transporters; and thirdly, phlorizin is
associated with frequent gastrointestinal
adverse events (AEs) including diarrhea and
dehydration [10]. Although these events are
usually attributed to phlorizin’s limited
selectivity for SGLT2 over SGLT1 (and
consequent presence of unabsorbed glucose
and galactose in the large intestine), early
studies with dual SGLT1/2 inhibitors suggest
SGLT1 inhibition is not inevitably associated
with gastrointestinal AEs [11]. Nevertheless, it
was clear that phlorizin was not suitable for
further development, but did serve as a basis for
the identification of inhibitors with improved
safety and tolerability profiles.
Empagliflozin Pharmacological
Characteristics and Mechanistic Studies
Extensive drug discovery and development
studies in vitro identified BI 10773
(empagliflozin; 1-chloro-4-[b-D-glucopyranos-1-
yl]-2-[4-([S]-tetrahydrofuran-3-yl-oxy)-benzyl]-
benzene; Fig. 2) as a potent and selective
competitive inhibitor of the SGLT2 protein.
Empagliflozin is structurally related to
phlorizin; however, while phlorizin is an
O-glucoside and thus susceptible to degradation
by b-glucosidase in the gastrointestinal tract,
empagliflozin is a C-glucoside, and the carbon–
carbon bond between the glucose and aglycone
moieties makes it resistant to gastrointestinal
degradation, allowing oral administration [5].
The pharmacokinetic and pharmacodynamic
(PK/PD) attributes of empagliflozin have been
extensively tested in vitro and in vivo, and
Table 1 shows key parameters for planned
therapeutic doses, 10 mg and 25 mg [12]. Early
studies included analysis of cell lines, stably
over-expressing human (h) SGLT1, SGLT2, or
SGLT4 receptors, which were screened for
specific cellular uptake of a radiolabeled test
molecule [14C]-alpha-methyl glucopyranoside.
In addition, two new cell lines over-expressing
hSGLT5 and hSGLT6 were established, and the
binding kinetics of [3H]-labeled empagliflozin
were also analyzed [13]. Taken together, these
studies demonstrated that empagliflozin is aFig. 2 Chemical structure of empagliﬂozin
Table 1 Summary of key pharmacokinetic parameters of









AUC0–t,ss (nmol h/L) 2,030 (362) 4,990 (1,080)
Cmax,ss (nmol h/L) 283 (90.1) 630 (106)
tmax,ss (h)
a 1.5 (1.0–2.0) 2.0 (0.7–4.2)
t1/2,ss (h) 14.3 (2.4) 10.7 (2.1)
Fe0–24,ss (%) 18.7 (4.5) 12.7 (6.4)
CLR, t,ss (mL/min) 34.4 (7.9) 23.5 (8.7)
Data are mean (SD) unless otherwise indicated
AUC area under concentration–time curve, Cmax
maximum plasma concentration, CLR renal clearance, Fe
fraction of dose that was excreted unchanged in urine, qd
once daily, SD standard deviation, ss steady state, t dosing
interval, t1/2 terminal half-life in plasma, tmax time to
maximum plasma concentration
a Median (range). Data are shown for the proposed
therapeutic doses (empagliﬂozin 2.5 mg and 100 mg were
also tested; for details, please see Heise et al. [12])
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potent inhibitor of hSGLT2, with a half
maximal inhibitory concentration (IC50) of
3.1 nM, and has [2,500-fold selectivity for
inhibition of SGLT2 versus SGLT1 [13].
Subsequent in vivo pharmacological studies
confirmed that empagliflozin lowered blood
glucose levels and improved glycemic control
in diabetic rodent models, with dose-dependent
increases in urinary glucose excretion (UGE)
[14]. In addition, 5 weeks of empagliflozin
treatment reduced HbA1c levels by 0.3% and
1.1% with 1 or 3 mg/kg, respectively, compared
with an increase of 1.1% in vehicle-treated
animals. Improved insulin sensitivity was also
recorded with empagliflozin [14].
The metabolic response to empagliflozin
has been studied in patients with T2DM [15].
As predicted from the theory of glucotoxicity,
reduction of blood glucose with empagliflozin
was associated with improvements in
measures of insulin resistance and beta-cell
function. The investigators also observed an
unexpected increase in endogenous glucose
production, possibly resulting from an
increase in plasma glucagon levels [15]. It
has been suggested that combination therapy
with an agent that inhibits glucagon by
increasing incretins (a GLP-1 mimetic or
DPP-4 inhibitor) may give synergistic effects
for the treatment of hyperglycemia, but this
work is still at early stages, and additional
studies are needed [16].
Empagliflozin Phase I Studies in Humans:
Safety, Tolerability, and Pharmacokinetics
Phase I studies of single doses of empagliflozin
were conducted in a study of 72 healthy male
volunteers recruited at a single clinic in
Germany. Subjects were randomized to an
empagliflozin dose of 0.5–800 mg, or placebo
[17]. Empagliflozin was quickly absorbed after
oral ingestion, with a median time to maximum
plasma concentration (tmax) of approximately
1.5–2.1 h, and total drug exposures were
generally proportional with escalating doses.
Empagliflozin also demonstrated a biphasic
decline in plasma concentrations during the
decay phase, with a terminal elimination half-
life ranging from 8.6 to 13.1 h [17].
In these healthy volunteers, the rate of UGE
increased with escalating doses, and reached a
plateau around the 50-mg dose. The mean total
amounts of glucose excreted in the urine during
24 h after administration of empagliflozin (0.5,
2.5, 10, 25, 50, 100, 200, 400, and 800 mg) were
3.1, 30.6, 47.9, 56.5, 63.6, 78.6, 69.1, 90.8, and
61.6 g, respectively, versus 0.06 g with placebo
[17]. The amounts of glucose excreted in the
urine were similar under fed and fasted
conditions, indicating food had no clinically
relevant effects on drug absorption. In these
healthy volunteers, empagliflozin had a good
safety profile and was well tolerated: reported
AEs included headaches, nervous system and
gastrointestinal disorders; all were reported at
similar frequencies in empagliflozin and
placebo-treated subjects, and none were
dose-dependent. There was one report of
hypoglycemia, which was observed 3 h after
an oral glucose tolerance test. Since the
glucose levels showed mild hypoglycemia
(53 mg/dL), it was considered to be reactive
hypoglycemia, and therefore not related to
study drug [17].
Similar results were seen in another Phase I
study of empagliflozin doses ranging from 1 to
100 mg in 48 healthy Japanese men [18].
Empagliflozin was rapidly absorbed in these
subjects, with a tmax of 1.25–2.50 h, after which
plasma concentrations declined with classic
biphasic kinetics. Empagliflozin exposures
were proportional to doses studied. At the
highest doses tested (100 mg), mean UGE was
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approximately 74 g and UGE was dose-
dependent. Empagliflozin was again well
tolerated, with no reports of hypoglycemia in
any of the subjects [18].
Following these results in healthy
volunteers, a study of empagliflozin safety,
tolerability, and PK/PD was conducted over
28 days in patients with T2DM [19]. Seventy-
eight patients received placebo (n = 16) or
empagliflozin once-daily at one of three doses:
10 mg (n = 16), 25 mg (n = 16), or 100 mg
(n = 30). Twice as many patients were
randomized to the 100-mg safety arm of this
study to assess the safety of this high dose of
empagliflozin.
Plasma concentrations of empagliflozin were
dose-dependent over the full range of doses
(10–100 mg) and linear PK were observed [19].
By Day 1, UGE rose from baseline to 74, 90, and
81 g with increasing doses of empagliflozin (10,
25, and 100 mg, respectively). Elevated UGE
continued throughout the 28 days of
empagliflozin treatment, while virtually no
change in UGE was observed with placebo
over the same timeframe [19]. Mean daily
plasma glucose and fasting plasma glucose
(FPG) levels were significantly reduced from
baseline in the empagliflozin groups compared
with the placebo group [19]. The incidence of
AEs was similar, with 50.0, 56.3, and 66.7% of
patients in the empagliflozin 10-mg, 25-mg,
and 100-mg groups, respectively, experiencing
at least one AE versus 62.5% with placebo. The
most commonly reported AEs were pollakiuria
(10.3%), nasopharyngitis (9.0%), constipation
(9.0%), and headache (7.7%) [19].
Additional trials addressing the safety,
tolerability, and PK/PD of empagliflozin in
patients with either renal or hepatic
impairment have recently been reported. An
open-label trial grouped 40 patients by
estimated glomerular filtration rate to study
the impact of renal impairment on the PK/PD
profile of a single dose of empagliflozin 50 mg
[20]. In patients with renal impairment, peak
plasma concentrations of empagliflozin were
similar to those with normal renal function. In
comparison to patients with normal renal
function, total plasma exposure (area under
the concentration–time curve from zero to
infinity) and the maximum plasma
concentration (Cmax) were modestly increased
(Table 2), most likely owing to decreased renal
clearance of the drug. Patients with mild or
moderate renal impairment had slightly
decreased UGE compared with patients with
normal renal function; those with severe
impairment or renal failure had lower UGE.
This suggests that while empagliflozin may be
used without dose adjustments in patients with
any degree of renal impairment, reductions in
plasma glucose levels would be predicted to be
less clinically meaningful for those with severe
renal impairment [20].
A related open-label clinical trial, also using a
single 50-mg dose of empagliflozin, compared
36 patients with various degrees of hepatic
impairment: eight each with mild [Child–Pugh
class A (5–6 points)], moderate [Child–Pugh
class B (7–9 points)], or severe [Child–Pugh class
C (10–15 points)] hepatic impairment, and 12
matched controls with normal hepatic function
[21]. Use of SGLT2 inhibitors in patients with
impaired hepatic function has been an area of
potential concern following a case of liver
toxicity with dapagliflozin, although after
longer follow-up the case was re-classified as
auto-immune hepatitis rather than drug-
induced liver injury, and data from additional
exposure to dapagliflozin have been reassuring
[22]. In the empagliflozin study, the drug was
rapidly absorbed and after achieving peak
concentrations, the expected biphasic decline
in plasma drug concentrations was observed
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[21]. PK parameters were mildly elevated, but
were less than twofold the values in patients
with normal hepatic function. While ongoing
vigilance is always prudent, the study
investigators concluded there is no need for
adjustment of empagliflozin doses in patients
with hepatic impairment [21].
Empagliflozin: Coadministration
with Other Drugs and Cardiac Safety
Patients with T2DM vary widely in age and
often have significant comorbidities, including
advanced cardiovascular disease; therefore, this
patient population often is receiving several
medications concurrently in addition to other
anti-diabetes drugs [23]. Accordingly, any
potential adverse interactions between
empagliflozin and other commonly prescribed
drugs are of clinical interest.
Coadministration with a number of
clinically important drugs that could
reasonably be expected to be prescribed in the
T2DM patient population has been tested in a
series of open-label, crossover studies in healthy
volunteers. These studies showed that
empagliflozin can be given together with the
anti-diabetes drugs metformin or sitagliptin, the
commonly prescribed cardiovascular drugs
verapamil, ramipril, and digoxin, and the
anticoagulant warfarin; in each case without
the need for dose adjustment for either
empagliflozin or the coadministered drug
[24–27]. In a similar open-label study, researchers
demonstrated a combined oral contraceptive
ethinylestradiol 30 lg/levonorgestrel 150 lg
once daily can be coadministered with oral
empagliflozin 25 mg once daily, without
requirement for dose adjustment [28].
A number of drugs are known to prolong the
cardiac QT interval, which can lead to life-
threatening arrhythmias in treated patients
[29]. To assess the cardiac safety of
empagliflozin, 30 volunteers with a mean age
of 35 years were randomized to a double-blind,
placebo-controlled study of single doses of
Table 2 Empagliﬂozin pharmacokinetics after administration of a single 50-mg dose in patients with renal or hepatic
impairment
Impairment severity Total plasma exposure
AUC0–? (nmol h/L)
Cmax,ss (nmol/L)
Renal impairment study [20]
Mild (n = 9) 118.2% (96.2, 145.4) 118.8% (93.6, 150.8)
Moderate (n = 7) 119.9% (96.3, 149.5) 102.3% (79.3, 131.9)
Severe (n = 8) 166.3% (134.4, 205.7) 120.7% (94.4, 154.3)
Failure/ESRD (n = 8) 148.3% (119.9, 183.4) 103.8% (81.2, 132.6)
Hepatic impairment study [21]
Mild (n = 8) 123.15% (98.9, 153.4) 103.8% (82.3, 131.0)
Moderate (n = 8) 146.97% (118.0, 183.0) 123.3% (97.7, 155.6)
Severe (n = 8) 174.70% (140.3, 217.6) 148.4% (117.7, 187.2)
For both studies, values are adjusted GMR (impaired/normal group) with 90% CI for adjusted GMR
AUC area under the concentration–time curve, CI conﬁdence interval, Cmax,ss maximum plasma concentration at steady
state, ESRD end-stage renal disease, GMR geometric mean ratio
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empagliflozin, 25 and 200 mg (therapeutic and
supratherapeutic, respectively), versus placebo
and open-label moxifloxacin 400 mg as positive
control [30]. Within the initial 1–4 h after
empagliflozin dosing, the placebo-corrected
mean change from baseline in the population
heart rate corrected QT interval was 0.6 ms
[90% confidence interval (CI) -0.7, 1.9] for
empagliflozin 25 mg and -0.2 ms (90% CI -1.4,
0.9) for empagliflozin 200 mg. These values are
deemed acceptable since the upper limit of the
confidence intervals are \10 ms, which is the
International Conference on Harmonization
E14 threshold for regulatory concern [31].
Consistent with the results seen in other trials,
the tolerability of empagliflozin was good for all
study participants, with 23.3% of the
empagliflozin group experiencing AEs with
empagliflozin compared with 27.6% of the
placebo group.
Empagliflozin in Phase II and Phase III
Clinical Trials
The favorable data emerging from the various
empagliflozin Phase I clinical trials set the stage
for subsequent Phase II and Phase III studies in
various patient populations. While several trials
are ongoing, a number have already been
reported in the peer-reviewed literature [32–36].
Phase II Trials
In a Phase II, randomized, double-blind,
placebo-controlled clinical trial, the safety,
efficacy, tolerability, and PK of empagliflozin
were evaluated in patients with T2DM [32].
The investigators randomized 408 patients
(treatment-naı¨ve or having completed a
4-week washout) to empagliflozin (5, 10, or
25 mg once daily), placebo, or open-label
metformin for 12 weeks. At baseline, the
mean ± standard deviation (SD) HbA1c level
across all groups was 7.9 ± 0.8%. After 12 weeks,
dose-dependent reductions in HbA1c from
baseline were seen in the empagliflozin-treated
patients (5 mg -0.4%, 10 mg -0.5%, 25 mg
-0.6%; p\0.0001 for all doses vs. placebo
?0.1%). Patients in the open-label metformin
arm had similar reductions in HbA1c levels of
-0.7%, but the metformin arm was not
designed to be tested for significance against
the double-blind groups [32].
Among the secondary endpoints, FPG levels
also decreased with empagliflozin (5 mg
-1.29 mmol/L, 10 mg -1.61 mmol/L, 25 mg
-1.72 mmol/L; all doses p\0.0001 vs. placebo
?0.04 mmol/L). Of special significance to
patients with T2DM, who tend to be either
overweight or obese, there were modest but
significant decreases in body weight in each of
the empagliflozin-treated groups, with changes
from baseline of -1.81 kg, -2.33 kg, and
-2.03 kg in the 5, 10, and 25-mg groups,
respectively (all p\0.001 vs. placebo); the
open-label metformin group had a -1.32 kg
decrease versus baseline [32].
The groups had similar rates of AEs, at
32.9% for the placebo group and 29.1% across
the empagliflozin groups. Few differences
between groups were observed for the most
common AEs reported with empagliflozin;
these were pollakiuria (3.3% vs. 0% for
placebo), thirst (3.3% vs. 0% for placebo), and
nasopharyngitis (2.0% vs. 1.2% for placebo)
[32]. There were AEs considered consistent
with urinary tract infections (UTIs) in 4/244
patients (1.6%) on empagliflozin and 1/82
patients (1.2%) on placebo. Genital infections
were reported in five patients (2%) on
empagliflozin versus none on placebo. No
patients discontinued due to UTIs or genital
infections [32].
A second Phase II study was undertaken to
evaluate the efficacy and safety of empagliflozin
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as an add-on therapy to metformin. The
investigators randomized 495 patients with
T2DM who were inadequately controlled on
metformin (HbA1c[7% to B10%) to double-
blind empagliflozin (1, 5, 10, 25, or 50 mg once
daily) or placebo, or to open-label sitagliptin
100 mg once daily, in addition to metformin for
12 weeks [33]. At baseline (while on stable
metformin), mean HbA1c across the seven
groups ranged from 7.8 to 8.1%. After
12 weeks, mean HbA1c increased by 0.15%
in the placebo group, compared with
reductions of -0.1%, -0.2%, -0.6%, -0.6%,
and -0.5% with empagliflozin 1, 5, 10, 25, or
50 mg, respectively, once daily (all were
significant with the exception of 1 mg
empagliflozin) [33]. In addition, empagliflozin
doses of 5–50 mg significantly reduced FPG
levels at 12 weeks, with mean reductions of -2
to -28 mg/dL compared with an increase of
5 mg/dL with placebo (all p\0.0001).
Empagliflozin was also associated with body
weight reductions after 12 weeks (-2.3 to -2.9 kg
with empagliflozin 5–50 mg vs. -1.2 kg with
placebo; p\0.01) [33].
In this study, empagliflozin was generally
well tolerated, and reported frequencies of AEs
were similar in the three main treatment
groups: empagliflozin (29.6–48.6%), placebo
(36.6%), and sitagliptin (35.2%), and the
reported rates of hypoglycemia were low and
balanced among the groups. The most frequent
AEs were UTIs (4.0% vs. 2.8%; empagliflozin vs.
placebo) and pollakiuria (2.5% vs. 1.4%;
empagliflozin vs. placebo). Genital infections
(4.0%) were reported only in the empagliflozin-
treated patients [33].
In these Phase II studies, empagliflozin
treatment led to dose-dependent, clinically
meaningful reductions in HbA1c and FPG,
along with concomitant reductions in body
weight compared with placebo-treated patients
after 12 weeks, indicating empagliflozin can be
efficacious as monotherapy or as add-on
therapy for patients with T2DM who are not
meeting their treatment goals on metformin
alone.
Phase III Trials
The Phase III clinical trial program evaluating
empagliflozin in patients with T2DM reportedly
includes more than 10 multinational trials,
between them enrolling more than 14,500
patients, including patients across a wide age
range and with a diversity of concomitant
diseases [37]. At the time of writing, three
Phase III trials have been published in detail,
and are reviewed below.
In the first of these Phase III trials, the
efficacy and safety of empagliflozin
monotherapy was investigated in a
randomized, placebo-controlled study of
patients with T2DM with HbA1c levels of
7–10% who were treatment-naı¨ve or had not
received medication over the 12 weeks
preceding the trial [34]. Patients were
randomized to empagliflozin 10 mg (n = 224),
empagliflozin 25 mg (n = 224), placebo
(n = 228), or sitagliptin 100 mg (n = 223) once
daily [34]. Patients with HbA1c[10% at
screening were not randomized, but were
assigned open-label empagliflozin 25 mg for
24 weeks (n = 87).
At 24 weeks, the randomized empagliflozin
groups had significant improvements in HbA1c,
FPG, and body weight compared with placebo,
as shown in Tables 3, 4, and 5 [34].
Furthermore, patients randomized to
empagliflozin were more likely to achieve an
HbA1c target of \7.0% at week 24: among
patients who had HbA1c levels C7.0% at
baseline, 35% of the empagliflozin 10-mg
group and 44% of the 25-mg group achieved
HbA1c\7.0% compared with 12% of the
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placebo group (odds ratio for empagliflozin
10 mg vs. placebo: 4.12; 95% CI 2.44, 6.97;
p\0.0001 and for empagliflozin 25 mg vs.
placebo 6.15; 95% CI 3.65, 10.36; p\0.0001).
Both empagliflozin groups also had significant
reductions from baseline in systolic blood
pressure versus placebo (empagliflozin 10 mg
-2.6 mmHg; 95% CI -4.9, -0.4; p = 0.0231;
empagliflozin 25 mg -3.4 mmHg; 95% CI -5.7,
-1.2; p = 0.0028) [34].
For patients assigned open-label empagliflozin,
no formal statistical analyses were performed, but
the investigators noted large reductions from
baseline to 24 weeks in HbA1c (-3.7%; 95% CI
-4.1, -3.3), with 28% of these patients reaching
HbA1c\7.0% by week 24. The group also had
large reductions in FPG (-4.86 mmol/L; 95% CI
-5.55, -4.16), and mean changes in weight
(-2.43 kg; 95% CI -3.50, -1.37) and systolic
blood pressure (-4.0 mmHg; 95% CI -7.1, -0.9)
of a similar level to changes in the empagliflozin
25-mg randomized group.
The majority of AEs were mild, with similar
proportions reported in each treatment arm
[placebo group, 140 (61%); empagliflozin
10 mg, 123 (55%); empagliflozin 25 mg, 135
(60%); and sitagliptin, 119 (53%)]. Serious AEs
also occurred in similar proportions of patients
[placebo group, 6 (3%); empagliflozin 10 mg,
8 (4%); empagliflozin 25 mg, 5 (2%); and
sitagliptin, 6 (3%)] [34]. The most common AE
was hyperglycemia, which was reported in 35
(15%) placebo patients, five (2%) empagliflozin
10-mg patients, four (2%) empagliflozin 25-mg
patients, and 13 (6%) sitagliptin patients. The
second most common AE was nasopharyngitis,
Table 3 Changes in HbA1c with empagliﬂozin in Phase III clinical trials
Treatment Baseline mean Adjusted mean change (95% CI)
versus placebo at 24 weeks
Monotherapy [34]
Empagliﬂozin 10 mg qd (n = 224) 7.9 (0.9)a -0.74% (-0.88, -0.59; p\0.0001)
Empagliﬂozin 25 mg qd (n = 224) 7.9 (0.9)a -0.85% (–0.99, -0.71; p\0.0001)
Sitagliptin 100 mg qd (n = 223) 7.9 (0.8)a -0.73% (–0.88, -0.59; p\0.0001)
Add-on to metformin [38]
Empagliﬂozin 10 mg qd (n = 217) 7.9 (0.1)b -0.57% (-0.70, -0.43; p\0.001)
Empagliﬂozin 25 mg qd (n = 213) 7.9 (0.1)b -0.64% (-0.77, -0.50; p\0.001)
Add-on to metformin ? sulfonylurea [35]
Empagliﬂozin 10 mg qd (n = 225) 8.1 (0.8)a -0.64% (-0.77, -0.51; p\0.001)
Empagliﬂozin 25 mg qd (n = 216) 8.1 (0.8)a -0.59% (-0.73, –0.46; p\0.001)
Add-on to pioglitazone ± metformin [36]
Empagliﬂozin 10 mg qd (n = 165) 8.1 (0.9)a -0.48% (-0.66, -0.29; p\0.001)
Empagliﬂozin 25 mg qd (n = 168) 8.1 (0.8)a -0.61% (-0.79, -0.42; p\0.001)
Trials published December 1, 2013. All values are %
CI conﬁdence interval, HbA1c glycosylated hemoglobin, qd once daily, SD standard deviation, SE standard error
a Baseline mean (SD)
b Baseline mean (SE)
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which was reported in 17 (7%) placebo patients,
16 (7%) empagliflozin 10-mg patients, 11 (5%)
empagliflozin 25-mg patients, and 15 (7%)
sitagliptin patients. Rates of hypoglycemia
were \1% in all treatment groups [34].
Laboratory measurements included serum
lipids and plasma uric acid concentrations
(Tables 6, 7). Of note, empagliflozin appeared
to be associated with improvements in uric acid
compared with placebo. In addition, compared
with placebo, high-density lipoprotein (HDL)-
cholesterol increased significantly from baseline
in patients treated with empagliflozin 10 or
25 mg, but levels of total cholesterol, low-
density lipoprotein (LDL)-cholesterol, or
triglycerides did not change [34].
The safety and efficacy of empagliflozin as
add-on therapy in patients with T2DM
receiving metformin with or without a
sulfonylurea was assessed in a randomized,
double-blind Phase III trial; two sub-studies
were defined by the patients’ background
medication at screening. In the first part of the
study, patients on metformin only were
randomized to 24 weeks of double-blind
treatment with either empagliflozin 10 mg
(n = 217) or 25 mg (n = 213) once daily or
placebo (n = 207) [38]. As with the previous
trial, patients with HbA1c[10% at screening
were not randomized, and instead were
included in an open-label empagliflozin 25-mg
arm (n = 69).
Table 4 Changes in fasting plasma glucose with empagliﬂozin in Phase III clinical trials
Treatment Baseline Change at 24 weeks
Monotherapy [34]
Empagliﬂozin 10 mg qd (n = 223) 8.48 (1.79)a -1.73 (-2.03, -1.43; p\0.0001)b
Empagliﬂozin 25 mg qd (n = 223) 8.47 (1.89)a -2.01 (-2.31, -1.71; p\0.0001)b
Sitagliptin 100 mg qd (n = 223) 8.16 (1.60)a -1.04 (-1.34 to -0.73; p\0.0001)b
Add-on to metformin [38]
Empagliﬂozin 10 mg qd (n = 217) 8.60 (0.13)c -1.11 (0.10); p\0.001 vs. placebod
Empagliﬂozin 25 mg qd (n = 213) 8.29 (0.12)c -1.24 (0.10); p\0.001 vs. placebod
Placebo (n = 207) 8.66 (0.12)c ?0.35 (0.10)d
Add-on to metformin ? sulfonylurea [35]
Empagliﬂozin 10 mg qd (n = 225) 8.38 (1.82)a -1.60 (-1.90, -1.30; p\0.001)b
Empagliﬂozin 25 mg qd (n = 216) 8.69 (1.87)a -1.60 (-1.90, -1.29; p\0.001)b
Add-on to pioglitazone ± metformin [36]
Empagliﬂozin 10 mg qd (n = 165) 8.44 (2.12)a -1.30 (-1.71, -0.90; p\0.001)b
Empagliﬂozin 25 mg qd (n = 168) 8.43 (2.05)a -1.58 (-1.98, -1.18; p\0.001)b
Trials published December 1, 2013. All values are mmol/L; to convert mmol/L to mg/dL multiply by 18.0182
qd once daily, SD standard deviation, SE standard error
a Baseline mean (SD)
b Adjusted mean change (95% CI) versus placebo at 24 weeks
c Baseline (SE)
d Change from baseline (SE)
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Preliminary results have been presented, and
support the use of empagliflozin as add-on
treatment to metformin, with the
empagliflozin groups having significant
improvements in HbA1c, FPG, and body
weight compared with placebo after 24 weeks
(Tables 3, 4, 5) [38]. Among patients who had
HbA1c levels C7.0% at baseline, 13% of the
placebo group achieved an HbA1c\7.0% by
24 weeks compared with 38% of the
empagliflozin 10-mg group (odds ratio, 4.72;
p\0.001 vs. placebo) and 39% of the
empagliflozin 25-mg group (odds ratio, 4.67;
p\0.001 vs. placebo). Of note, a weight loss of
[5% of body weight was achieved by 4.8% of
patients in the placebo arm after 24 weeks,
compared with 21.2% on empagliflozin 10 mg,
and 23.0% on empagliflozin 25 mg [38]. The
empagliflozin groups also had significant
reductions in systolic blood pressure, with
mean changes of -4.5 ± 0.7 mmHg in the
10-mg group and -5.2 ± 0.7 mmHg in the
25-mg group.
For the group of patients with very high
HbA1c at screening, who were assigned open-
label empagliflozin 25 mg in addition to their
background metformin, HbA1c fell by a
mean ± standard error (SE) of -3.2 ± 0.2%
from a baseline mean of 11.1 ± 0.2%.
Improvement was also seen in FPG, with a
mean ± SE reduction of -3.02 ± 0.57 mmol/L,
from a baseline mean of 11.30 ± 0.43 mmol/L.
The group also had reductions from baseline
in body weight (mean ± SE -1.91 ± 0.59 kg)
and systolic blood pressure (mean ± SE
-2.4 ± 1.6).
Table 5 Changes in body weight with empagliﬂozin in Phase III clinical trials
Treatment Baseline Adjusted mean change (95% CI)
versus placebo at 24 weeks
Monotherapy [34]
Empagliﬂozin 10 mg qd (n = 224) 78.4 (18.7)a -1.93 (-2.41, -1.45; p\0.0001)
Empagliﬂozin 25 mg qd (n = 224) 77.8 (18.0)a -2.15 (-2.63, -1.67; p\0.0001)
Sitagliptin 100 mg qd (n = 223) 79.3 (20.4)a ?0.52 (0.04, 1.00; p\0.0355)
Add-on to metformin [38]
Empagliﬂozin 10 mg qd (n = 217) 81.6 (1.3)b -1.63 (-2.11, -1.15; p\0.001)
Empagliﬂozin 25 mg qd (n = 213) 82.2 (1.3)b -2.01 (-2.49, -1.53; p\0.001)
Add-on to metformin ? sulfonylurea [35]
Empagliﬂozin 10 mg qd (n = 225) 77.1 (18.3)a -1.76 (-2.19, -1.34; p\0.001)
Empagliﬂozin 25 mg qd (n = 216) 77.5 (18.8)a -1.99 (-2.42, -1.56; p\0.001)
Add-on to pioglitazone ± metformin [36]
Empagliﬂozin 10 mg qd (n = 165) 78.0 (19.1)a -1.95 (-2.55, -1.36; p\0.001)
Empagliﬂozin 25 mg qd (n = 168) 78.9 (19.9)a -1.81 (-2.41, -1.22; p\0.001)
Trials published December 1, 2013. All values are kilograms
CI conﬁdence interval, qd once daily, SD standard deviation, SE standard error
a Baseline mean (SD)
b Baseline mean (SE)
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In this trial, AEs were reported by 57.1%,
49.5%, and 58.7% of patients on empagliflozin
10 mg, empagliflozin 25 mg, and placebo,
respectively. Hypoglycemia (defined as
plasma glucose B70 mg/dL, and/or requiring
assistance) was reported in very low
proportions of patients (1.8% in the
empagliflozin 10-mg arm, 1.4% in the
empagliflozin 25-mg arm, and 0.5% in the
placebo arm), and none of the cases required
assistance [38]. AEs consistent with UTIs were
reported in low proportions across the
treatment arms (5.1%, 5.6%, and 4.9% in the
empagliflozin 10-mg, 25-mg, and placebo
arms, respectively). Rates of AEs associated
with genital infection were also low with
empagliflozin, but appeared more frequent
than with placebo (3.7% and 4.7% in the
10-mg and 25-mg empagliflozin arms vs.
none in patients receiving placebo) [38].
In the second part of the study, patients with
HbA1c inadequately controlled on metformin
and a sulfonylurea were randomized to add on
once-daily empagliflozin 10 mg (n = 225),
empagliflozin 25 mg (n = 216), or placebo
(n = 225) for 24 weeks [35]. Improvements
were seen in glycemic control, with reductions
in HbA1c levels after 24 weeks being
significantly greater in the empagliflozin-
treated groups, as were reductions in FPG and
body weight, as shown in Tables 3, 4, and 5 [35].
Patients were more likely to achieve
HbA1c\7.0% with empagliflozin, with 26.3%
of the empagliflozin 10-mg group reaching this
goal (odds ratio vs. placebo 3.85; 95% CI 2.17,
6.85; p\0.001) and 32.2% in the empagliflozin
Table 7 Changes in plasma uric acid with empagliﬂozin in Phase III clinical trials
Treatment Baseline mean (SD) Change from
baseline, mean (SD)
Monotherapy [34]
Empagliﬂozin 10 mg qd (n = 224) 293 (109) -58 (80)
Empagliﬂozin 25 mg qd (n = 224) 297 (124) -62 (83)
Sitagliptin 100 mg qd (n = 223) 298 (114) ?17 (77)
Placebo (n = 228) 307 (133) -14 (91)
Add-on to metformin ? sulfonylurea [35]
Empagliﬂozin 10 mg qd (n = 225) 314 (127) -28 (87)
Empagliﬂozin 25 mg qd (n = 216) 298 (115) -26 (81)
Placebo (n = 225) 307 (110) ?11 (81)
Add-on to pioglitazone ± metformin [36]
Empagliﬂozin 10 mg qd (n = 165) 286 (116) -37 (83)
Empagliﬂozin 25 mg qd (n = 168) 272 (116) -29 (81)
Placebo (n = 165) 275 (113) ?13 (69)
Trials published December 1, 2013. All values are lmol/L; values were normalized to a standard reference range
qd once daily, SD standard deviation. The study of empagliﬂozin as add-on to metformin is not included in this table
because, at the time of writing, it has been published in preliminary form only, and the report did not include uric acid
results
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25-mg group (odds ratio vs. placebo 5.22; 95%
CI 2.95, 9.24; p\0.001). The effects of 24 weeks
of empagliflozin on body weight (Table 5) were
consistent with earlier reports, with significant
differences in the adjusted means for
empagliflozin versus placebo [35]. Reductions
in blood pressure were of a similar level to those
seen with empagliflozin used as monotherapy,
with a placebo-corrected reduction in the
empagliflozin 10-mg group of -2.7 mmHg
(95% CI -4.6, -0.8; p = 0.005) and in the
25-mg group of -2.1 (95% CI -4.0, -0.2;
p = 0.032).
In this study, 101 patients with HbA1c[10%
at screening were treated with open-label
empagliflozin 25 mg as add-on to stable
metformin and sulfonylurea. The mean ± SE
change from baseline in HbA1c at week 24 was
-2.9 ± 0.2%, and the mean value fell from
11.2 ± 1.3% at baseline to 8.2 ± 0.1% at week
24. At week 24, the mean ± SE change from
baseline in FPG was -3.02 ± 0.37 mmol/L,
change in body weight was -1.76 ± 0.40 kg,
and change in systolic blood pressure was
-4.3 ± 1.2 mmHg.
AEs were reported at similar proportions
across treatment groups, at 67.9% in the
empagliflozin 10-mg group, 64.1% in the
empagliflozin 25-mg group, and 62.7% in the
placebo group [35]. Events consistent with UTIs
were reported in 10.3% and 8.3% of the
empagliflozin 10-mg and 25-mg groups,
respectively, versus 8.0% of the placebo group,
while events consistent with genital infections
were reported in 2.7% and 2.3% of the respective
empagliflozin groups versus 0.9% of the placebo
group [35]. For LDL-cholesterol and triglycerides,
there were no significant differences compared
with placebo, while there was a small increase in
HDL-cholesterol (Table 6). In the randomized
empagliflozin groups, there were small decreases
in uric acid (Table 7).
The third Phase III trial published is a
randomized, double-blind, placebo-controlled
trial that examined the efficacy and safety of
empagliflozin in patients with T2DM who were
on pioglitazone at screening; patients could also
be receiving metformin [36]. Patients were
randomized and treated with once-daily
empagliflozin 10 mg (n = 165), 25 mg
(n = 168), or placebo (n = 165) for 24 weeks
[36]. Unlike the aforementioned trials, the
design of this study did not include an open-
label arm for patients with very high HbA1c at
screening.
The investigators found that 24 weeks of
empagliflozin treatment resulted in significant
reductions in HbA1c and FPG (Tables 3, 4), and
more patients with HbA1c C7.0% at baseline
achieved HbA1c\7.0% with empagliflozin
10 mg (23.8%) and 25 mg (30.0%) than with
placebo (7.7%) (odds ratio for empagliflozin
10 mg vs. placebo: 3.85; 95% CI 1.88, 7.92;
p\0.001; odds ratio for empagliflozin 25 mg vs.
placebo: 5.02; 95% CI 2.49, 10.12; p\0.001).
Empagliflozin was also associated with
significant reductions in body weight (Table 5)
and larger proportions of patients experienced
reduction of [5% of body weight (18.8% and
13.7% of patients receiving 10 mg and 25 mg of
empagliflozin, compared with 5.5% of patients
receiving placebo). Empagliflozin was also
associated with reductions in blood pressure
compared with placebo: systolic blood pressure
fell by -3.9 mmHg (95% CI -6.23, -1.50;
p = 0.001) with empagliflozin 10 mg and
-4.7 mmHg (95% CI -7.08, -2.37; p\0.001)
with empagliflozin 25 mg [36].
In this study, as in previous studies,
empagliflozin was well tolerated and the
incidence of AEs was not significantly different
from placebo. Similar rates of AEs were reported
in all three treatment arms (67.3%, 71.4%, and
72.7% of patients in the 10-mg, 25-mg, and
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placebo groups, respectively). Rates of reported
hypoglycemia (plasma glucose B70 mg/dL and/
or requiring assistance) were also similar across
treatment arms (1.2%, 2.4%, and 1.8% of the
respective groups), and no patient required
assistance. The proportion of patients with AEs
related to UTIs was similar across groups
(17.0%, 11.9%, and 16.4% of patients on
10 mg, 25 mg, and placebo, respectively);
events consistent with genital infection were
seen more commonly with empagliflozin (8.5%,
3.6%, and 2.4% of patients on 10 mg, 25 mg,
and placebo, respectively); however, all were
mild or moderate in intensity and none led to
premature study discontinuation [36].
Measurement of serum lipids showed
significant increase in HDL-cholesterol in the
empagliflozin 10-mg group, but a non-
significant increase in the 25-mg group
(Table 6). No significant differences were
reported for total cholesterol, LDL-cholesterol,
or triglycerides in either of the empagliflozin
treatment arms (Table 6). Again, small decreases
were seen in uric acid levels with empagliflozin,
of approximately the same level seen in the
study of empagliflozin as add-on to metformin
plus sulfonylurea (Table 7).
Anticipated Results: Recently Completed
or Ongoing Clinical Trials
The clinical development program for
empagliflozin is at a relatively advanced stage;
nonetheless, further Phase II and Phase III
studies are either recently completed or in
progress, and additional Phase III trials
registered on the US National Institutes of
Health registry at ClinicalTrials.gov are shown
in Table 8 [43–49]. Given the number of options
available for treatment of T2DM, empagliflozin
will need to be assessed as add-on therapy to
insulin, among other agents, as well as in initial
combination therapies. The Phase III studies
reported above were placebo-controlled, but
to draw definite conclusions regarding
comparative efficacy, an active-controlled
study is required, and a 4-year Phase III trial of
empagliflozin versus glimepiride is underway
[39]. Studies are also required to investigate
blood pressure profiles in hypertensive patients,
as well as effects in patients with renal
impairment, and studies in these groups have
reported preliminary data [40, 41]. The
empagliflozin Phase III program also includes a
cardiovascular outcome event trial, enrolling
approximately 7,000 patients at high
cardiovascular risk [42]. Japanese regulatory
authorities also require a range of trials in
Japanese patients, and these are underway.
Clearly, the number of clinical trials that are
expected to report in the near future will provide
a wealth of data on the safety and efficacy of
empagliflozin treatment, to help optimize
treatment regimens for individual patients.
CONCLUSIONS
Based on the evidence available to date,
empagliflozin appears to have a promising
pharmacologic profile. Pharmacodynamic and
pharmacokinetic characteristics include: (1)
very high selectivity for the SGLT2 over SGLT1
receptors, potentially minimizing off-target
effects; (2) predictable pharmacokinetics, and
no known drug–drug interactions with other
drugs commonly prescribed for this patient
population; (3) favorable pharmacodynamics,
including additive control of plasma glucose
levels via inhibition of reuptake in the kidney,
with a well-defined dose–response relationship;
(4) a good safety profile, with no increase in
hypoglycemia compared with placebo; and (5)
acceptable tolerability in all patient populations
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studied to date. The most common AEs reported
to date include nasopharyngitis, UTIs, and
genital tract infections. Changes in uric acid
and LDL-cholesterol are of considerable
interest—while the changes in uric acid appear
favorable, the changes in lipid profiles have
been less consistent between studies—yet it
must be remembered that these values were
captured as safety endpoints in the trials, and
thus any potential benefit cannot be defined
Table 8 Ongoing or recently completed empagliﬂozin Phase III clinical trials
Study population/NCT number Treatment arms Enrollment Duration Primary outcome measure(s)
Add-on to insulin
NCT01306214 [43]
(1) Empagliﬂozin 566 52 weeks Change from baseline in HbA1c
(2) Placebo
Head-to-head study vs. sulfonylurea
NCT01167881 [39]
(1) Empagliﬂozin 1,549 52 and
104 weeks
Change from baseline in HbA1c
(2) Glimepiride
Head-to-head study vs. DPP-4i
NCT01984606 [44]




(1) Empagliﬂozin 825 12 weeks Change from baseline in HbA1c
and mean 24-h systolic blood pressure(2) Placebo
T2DM and renal insufﬁciency
NCT01164501 [40]




(1) Empagliﬂozin 7,000 Up to
8 years
Time to any of CV deatha, nonfatal MI,
and nonfatal stroke(2) Placebo
Combination with metformin in
treatment-naı¨ve patients
NCT01719003 [45]




Add-on DPP-4i in patients on
empagliﬂozin and metformin
NCT01778049 [46]




Combination with DPP-4i in patients
on metformin
NCT01422876 [47]






(1) Linagliptin 444 24 weeks Change from baseline in HbA1c
(2) Empagliﬂozin and
linagliptin
Add-on to various agents in Japanese
patients
NCT01368081 [49]
(1) Empagliﬂozin 1,162 52 weeks Safety (adverse event frequency)
(2) Metformin
Phase III trials returned on a search of ‘‘empagliﬂozin’’ at ClinicalTrials.gov on November 29, 2013 are included, if not already reported in the
peer-reviewed literature, and therefore discussed elsewhere in the review. The following studies listed as Phase III studies on ClinicalTrials.gov are
not included: NCT01257334 appears to be a duplicate record for trial NCT01159600, NCT01947855 is a 4-week study with only 60 patients,
and NCT01289990 is a long-term extension study of completed Phase III trials
CV cardiovascular, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycosylated hemoglobin, MI myocardial infarction, T2DM type 2 diabetes
mellitus
a Including fatal stroke and fatal MI
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without further studies specifically comparing
these endpoints.
The addition of the SGLT2 inhibitors, with
their novel and insulin-independent
mechanism of action, to the collection of
available anti-diabetes therapies has a number
of implications for the clinical management of
diabetes. These include: (1) enhanced glycemic
control, without undue concerns with regard to
the development of hypoglycemia in treated
patients; (2) a novel, insulin-independent
treatment option for patients who have been
receiving insulin secretagogues for an extended
period of time, and may be experiencing
diminished responsiveness to these agents due
to beta-cell fatigue; (3) the ability to use these
drugs in patients who have significant co-
morbidities, including appropriate ranges of
renal and hepatic impairment without dose-
adjustment; and (4) the co-administration of the
SGLT2 inhibitors in patients who are currently
receiving commonly prescribed medications
including antihypertensive agents, anti-clotting
agents, and oral contraceptives, all without
clinically meaningful changes in the dosing of
any of these drugs.
Additional Phase II and Phase III trials are
underway and have been designed to test the
safety and efficacy of empagliflozin over longer
follow-up and in larger numbers of patients,
representing a broad range of clinical subtypes
(severity, duration, age, ethnicity, etc.). These
ongoing trials will provide key data on the
safety and efficacy of empagliflozin, often
in combination with other anti-diabetes
treatments, including cardiovascular outcomes
data in patients at high cardiovascular risk.
Therefore, patients and their healthcare
providers will be in an informed position to
leverage the potential of these drugs, in the
context of a growing movement toward more
individualized approaches to diabetes care.
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